DexmedetomidinePhase 3NCT05158348
A Comparative Study to Measure the Effect of Nebulized Dexmedetomidine
A Phase 3 study testing Dexmedetomidine Hydrochloride, Nebulized lidocaine and Local infiltration of lidocaine in people with Dexmedetomidine and Lidocaine, run by Kasr El Aini Hospital at 1 site in Egypt.
Trial summary
A comparative study to measure the effect of nebulized dexmedetomidine - lidocaine for controlling postoperative pain after tonsillectomy in adults. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Dexmedetomidine, Lidocaine, Tonsillectomy
- What is being tested?
- Dexmedetomidine Hydrochloride, Nebulized lidocaine and Local infiltration of lidocaine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 5 Nov 2021to 15 Apr 2022
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients of either sex, aged between 18-30 years old, ASA physical status I, II undergoing tonsillectomy.
Who cannot join
- Patients were excluded if they had clinically important coronary atherosclerotic heart disease, a history of stroke or transient ischemic attack, Sinus bradycardia or heart block, coagulopathy, peritonsillar abscess, any infection at the site of injection, Known allergy to the study drugs (lidocaine, dexmedetomidine).
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Cairo university hospitals
Cairo, 11559
Dina Mohamad, MD, 01005249134, dinamahmoud@kasralainy.edu.eg
About this study
Official title: A Comparative Study to Measure the Effect of Nebulized Dexmedetomidine - Lidocaine for Controlling Postoperative Pain After Tonsillectomy in Adults.
A comparative study to measure the effect of nebulized dexmedetomidine - lidocaine for controlling postoperative pain after tonsillectomy in adults.
Read the detailed description
Tonsillectomy is one of the most common procedures in ear, nose, and throat surgery. It is usually performed as a day-stay procedure. [1] Pain is the most common reason for physician contact after discharge, indicating that post-tonsillectomy pain is intense and undertreated. [2] Patients need analgesics that are effective and can be used safely at home.
Adults have a different pattern of pain compared with children; this is related to the different indications and techniques of tonsillectomy. [3, 4] In adults, the surgery is usually performed for chronic infection with scarred tonsils that requires dissection with coagulation, thus causing intense and longer-lasting pain. [5] In children, the indication is usually hypertrophy or recurrent acute infections with smaller changes in tonsil tissues than in adults. [6] Multimodal analgesia has become the standard of care in postoperative pain management. Combinations of analgesics with different sites or modes of action are commonly used to improve analgesia and to reduce the doses of individual analgesics (especially opioids) and to reduce adverse effects.
Systematic reviews on various analgesics for post-tonsillectomy pain have been published for paediatric and adolescent patients.(7,8) Paracetamol (alone and in combination with ibuprofen)NSAIDS,dexamethasone or gabapentenoids(9) Dexmedetomidine is a highly selective adrenergic α-2 agonist that does not cause respiratory depression and can be used as a sedative for various procedures. [10,11] Recently, the use of dexmedetomidine as an additive to local anaesthetics was reported to have several advantages over conventional intravenous administration. [12,13]
Nebulized dexmedetomidine combined with other anaesthetics as a premedication for outpatient paediatric dental procedures has also been reported to provide smoother induction of general anaesthesia with a more rapid recovery and no significant side effects. [14] Nebulized dexmedetomidine-lidocaine inhalation as a premedication for flexible bronchoscopy was well tolerated during bronchoscopies performed under moderate sedation and was associated with a reduced incidence of moderate to severe coughing, a shorter recovery time and reduced vasoconstrictor consumption(15).However, there are no data regarding the use of nebulized dexmedetomidine-lidocaine for controlling postoperative pain after tonsillectomy.
Comparative study II. Study setting and location This study will be conducted at Kasr Al-Ainy tertiary Hospital, Cairo University after being approved by the anesthesia department Research committee and obtaining written informed consent of patients III. Study population 60 patients undergoing tonsillectomy operation will be enrolled in this study divided into 3 groups each of 20 patients. Group A will receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine. Group B will receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine and group C will receive intra-operative local infiltration of lidocaine and post-operative nebulised saline.
IV. Eligibility Criteria
- Inclusion criteria Patients of either sex, aged between 18-50 years old, ASA physical status I, II undergoing tonsillectomy.
- Exclusion criteria Patients were excluded if they had clinically important coronary atherosclerotic heart disease, a history of stroke or transient ischemic attack, Sinus bradycardia or heart block, coagulopathy, peritonsillar abscess, any infection at the site of injection, Known allergy to the study drugs (lidocaine, dexmedetomidine).
- Study Procedures
- Randomization (in RCT only) All procedures will be performed by the same team, which include an ENT surgeon using the same technique in all study groups which is dissecting the tonsils by bipolar diathermy technique and surgeon will do the infiltration technique also and a specialized anaesthesiologist for the inhalational technique ,the patients will be informed about the procedure ,technique of the intra-operative and post-operative pain control and the VAS scoring system before the operation. Randomization and drug masking will be completed by a specialist who will not be directly involved in the trials. The patients will be divided into 3 groups; Group A will receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine. Group B will receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine and group C will receive intra-operative local infiltration of lidocaine and post-operative nebulised saline.
Study Protocol Upon arrival to the operating room, a pulse oximetry, capnography, continuous electrocardiogram (ECG), and non-invasive blood pressure measurement device will be connected to the patient. A large bore cannula will be inserted. Pre-medications will be given; Antiemetics as metclopromide(10mg) or dexamethasone(8mg) to decrease laryngeal edema postoperatively. Anesthesia will be induced with IV Propofol, 1.5 mg/kg and IV fentanyl 1 mic/kg and atracurium 0.5 mg/kg. Patients will be intubated and ventilated with oxygen maintaining ETCO2 at 35-40 mmHg. Anesthesia will be maintained with oxygen, isoflurane and atracurium providing muscle relaxation as a maintenance.
- Group A will receive intra-operative local infiltration of saline in tonsillar bed by the surgeon and post-operative nebulised dexametomidine(0.6mic per kg) and lidocaine(1 mic per kg)by specialized anesthesiologist. Group B will receive intra-operative local infiltration of saline by the surgeon and post-operative will receive neublised lidocaine(1 mic per kg) by specialized anesthesiologist and group C will receive intra-operative local infiltration of lidocaine(1 mic per kg) in the tonsillar bed by the surgeon and post-operative nebulised saline by the anesthesiologist.
- Conditions
- Dexmedetomidine, Lidocaine, Tonsillectomy
- Being tested
- Dexmedetomidine Hydrochloride, Nebulized lidocaine, Local infiltration of lidocaine
- Keywords
- Post tonsillectomy, Pain, Dexmedetomidine, Lidocaine
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dexmedetomidine HydrochlorideDrug
Group A will receive post-operative nebulised dexametomidine and lidocaine.
Nebulized lidocaineDrug
Group B will receive post-operative will receive nebulised lidocaine
Local infiltration of lidocaineDrug
group C will receive intra-operative local infiltration of lidocaine
| Study group | Role | What they receive |
|---|---|---|
| Group A | Active comparator | receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine. Receives: Drug: Dexmedetomidine Hydrochloride |
| Group B | Active comparator | receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine Receives: Drug: Nebulized lidocaine |
| Group C | Active comparator | receive intra-operative local infiltration of lidocaine and post-operative nebulised saline. Receives: Drug: Local infiltration of lidocaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative pain 4 hours after tonsillectomy measured by visual analogue score
Measured: 4 hours postoperative
Secondary outcomes (1)
Postoperative nausea and vomiting following tonsillectomy operation after1 hour , 2 hours and after 4 hours
Measured: 4 hours postoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2021
- Study start5 Nov 2021
- Primary completion10 Apr 2022 (estimated)
- Study completion15 Apr 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DexmedetomidineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kasr El Aini Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dina Mahmoud Mohamed, Kasr El Aini Hospital
- Investigators
- Dina Mohamed, Principal investigator, Egypt Cairo university hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05158348
- Sponsor's protocol ID
- MS-394-2020
- Status last verified
- Dec 2021
- First submitted
- 7 Dec 2021
- Last updated
- 15 Dec 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Study to Measure the Effect of Nebulized Dexmedetomidine - Lidocaine for Controlling Postoperative Pain After Tonsillectomy in Adults.
- ClinicalTrials.gov ID
- NCT05158348
- Acronym / sponsor ID
- MS-394-2020
- Conditions
- Dexmedetomidine, Lidocaine, Tonsillectomy
- Keywords
- Post tonsillectomy, Pain, Dexmedetomidine, Lidocaine
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Kasr El Aini HospitalUniversity, hospital or other
- Study start
- 5 Nov 2021 (actual)
- Primary completion
- 10 Apr 2022 (estimated)
- Study completion
- 15 Apr 2022 (estimated)
- First posted
- 15 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A comparative study to measure the effect of nebulized dexmedetomidine - lidocaine for controlling postoperative pain after tonsillectomy in adults.
Detailed description
Tonsillectomy is one of the most common procedures in ear, nose, and throat surgery. It is usually performed as a day-stay procedure. [1] Pain is the most common reason for physician contact after discharge, indicating that post-tonsillectomy pain is intense and undertreated. [2] Patients need analgesics that are effective and can be used safely at home.
Adults have a different pattern of pain compared with children; this is related to the different indications and techniques of tonsillectomy. [3, 4] In adults, the surgery is usually performed for chronic infection with scarred tonsils that requires dissection with coagulation, thus causing intense and longer-lasting pain. [5] In children, the indication is usually hypertrophy or recurrent acute infections with smaller changes in tonsil tissues than in adults. [6] Multimodal analgesia has become the standard of care in postoperative pain management. Combinations of analgesics with different sites or modes of action are commonly used to improve analgesia and to reduce the doses of individual analgesics (especially opioids) and to reduce adverse effects.
Systematic reviews on various analgesics for post-tonsillectomy pain have been published for paediatric and adolescent patients.(7,8) Paracetamol (alone and in combination with ibuprofen)NSAIDS,dexamethasone or gabapentenoids(9) Dexmedetomidine is a highly selective adrenergic α-2 agonist that does not cause respiratory depression and can be used as a sedative for various procedures. [10,11] Recently, the use of dexmedetomidine as an additive to local anaesthetics was reported to have several advantages over conventional intravenous administration. [12,13]
Nebulized dexmedetomidine combined with other anaesthetics as a premedication for outpatient paediatric dental procedures has also been reported to provide smoother induction of general anaesthesia with a more rapid recovery and no significant side effects. [14] Nebulized dexmedetomidine-lidocaine inhalation as a premedication for flexible bronchoscopy was well tolerated during bronchoscopies performed under moderate sedation and was associated with a reduced incidence of moderate to severe coughing, a shorter recovery time and reduced vasoconstrictor consumption(15).However, there are no data regarding the use of nebulized dexmedetomidine-lidocaine for controlling postoperative pain after tonsillectomy.
Comparative study II. Study setting and location This study will be conducted at Kasr Al-Ainy tertiary Hospital, Cairo University after being approved by the anesthesia department Research committee and obtaining written informed consent of patients III. Study population 60 patients undergoing tonsillectomy operation will be enrolled in this study divided into 3 groups each of 20 patients. Group A will receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine. Group B will receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine and group C will receive intra-operative local infiltration of lidocaine and post-operative nebulised saline.
IV. Eligibility Criteria
- Inclusion criteria Patients of either sex, aged between 18-50 years old, ASA physical status I, II undergoing tonsillectomy.
- Exclusion criteria Patients were excluded if they had clinically important coronary atherosclerotic heart disease, a history of stroke or transient ischemic attack, Sinus bradycardia or heart block, coagulopathy, peritonsillar abscess, any infection at the site of injection, Known allergy to the study drugs (lidocaine, dexmedetomidine).
- Study Procedures
- Randomization (in RCT only) All procedures will be performed by the same team, which include an ENT surgeon using the same technique in all study groups which is dissecting the tonsils by bipolar diathermy technique and surgeon will do the infiltration technique also and a specialized anaesthesiologist for the inhalational technique ,the patients will be informed about the procedure ,technique of the intra-operative and post-operative pain control and the VAS scoring system before the operation. Randomization and drug masking will be completed by a specialist who will not be directly involved in the trials. The patients will be divided into 3 groups; Group A will receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine. Group B will receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine and group C will receive intra-operative local infiltration of lidocaine and post-operative nebulised saline.
Study Protocol Upon arrival to the operating room, a pulse oximetry, capnography, continuous electrocardiogram (ECG), and non-invasive blood pressure measurement device will be connected to the patient. A large bore cannula will be inserted. Pre-medications will be given; Antiemetics as metclopromide(10mg) or dexamethasone(8mg) to decrease laryngeal edema postoperatively. Anesthesia will be induced with IV Propofol, 1.5 mg/kg and IV fentanyl 1 mic/kg and atracurium 0.5 mg/kg. Patients will be intubated and ventilated with oxygen maintaining ETCO2 at 35-40 mmHg. Anesthesia will be maintained with oxygen, isoflurane and atracurium providing muscle relaxation as a maintenance.
- Group A will receive intra-operative local infiltration of saline in tonsillar bed by the surgeon and post-operative nebulised dexametomidine(0.6mic per kg) and lidocaine(1 mic per kg)by specialized anesthesiologist. Group B will receive intra-operative local infiltration of saline by the surgeon and post-operative will receive neublised lidocaine(1 mic per kg) by specialized anesthesiologist and group C will receive intra-operative local infiltration of lidocaine(1 mic per kg) in the tonsillar bed by the surgeon and post-operative nebulised saline by the anesthesiologist.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group A | Active comparator | Drug: Dexmedetomidine Hydrochloridereceive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine. |
| Group B | Active comparator | Drug: Nebulized lidocainereceive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine |
| Group C | Active comparator | Drug: Local infiltration of lidocainereceive intra-operative local infiltration of lidocaine and post-operative nebulised saline. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Patients of either sex, aged between 18-30 years old, ASA physical status I, II undergoing tonsillectomy.
Key exclusion criteria (1 listed)
- Patients were excluded if they had clinically important coronary atherosclerotic heart disease, a history of stroke or transient ischemic attack, Sinus bradycardia or heart block, coagulopathy, peritonsillar abscess, any infection at the site of injection, Known allergy to the study drugs (lidocaine, dexmedetomidine).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dexmedetomidine HydrochlorideGroup A will receive post-operative nebulised dexametomidine and lidocaine. | Drug | Group A |
| Nebulized lidocaineGroup B will receive post-operative will receive nebulised lidocaine | Drug | Group B |
| Local infiltration of lidocainegroup C will receive intra-operative local infiltration of lidocaine | Drug | Group C |
Primary outcome
Postoperative pain 4 hours after tonsillectomy measured by visual analogue score
Time frame: 4 hours postoperative
1 secondary outcome
Postoperative nausea and vomiting following tonsillectomy operation after1 hour , 2 hours and after 4 hours
Time frame: 4 hours postoperative
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Dexmedetomidine
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Not yet recruiting
Adding Different Doses of Dexmedetomidine to Bupivecaine in Erector Spinae Plane Block
Postoperative Pain in Lumbar Spine Surgery
Recruiting
ACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty
Knee Osteoarthritis
Recruiting
Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults
Hip Osteoarthritis
Not yet recruiting
DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial)
Neurosurgery, Brain Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dina Mohamed principal investigator
Egypt Cairo university hospitals
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Dexmedetomidine Hydrochloride, Nebulized lidocaine and Local infiltration of lidocaine in people with Dexmedetomidine and Lidocaine, run by Kasr El Aini Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Dina Mohamed (01005249134, dinamahmoud@kasralainy.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative pain 4 hours after tonsillectomy measured by visual analogue score (time frame: 4 hours postoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2021.